PharmacyCodes



Colistimethate en es it fr

Colistimethate Brand names, Colistimethate Analogs

Colistimethate Brand Names Mixture

  • No information avaliable

Colistimethate Chemical_Formula

C58H105N16Na5O28S5

Colistimethate RX_link

http://www.rxlist.com/cgi/generic2/colistimethate.htm

Colistimethate fda sheet

Colistimethate msds (material safety sheet)

Colistimethate MSDS

Colistimethate Synthesis Reference

No information avaliable

Colistimethate Molecular Weight

1749.82 g/mol

Colistimethate Melting Point

No information avaliable

Colistimethate H2O Solubility

Appreciable

Colistimethate State

Solid

Colistimethate LogP

No information avaliable

Colistimethate Dosage Forms

Vials containing colistimethate sodium or pentasodium colistinmethanesulfonate (150 mg colistin base activity) for injection.

Colistimethate Indication

For the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli, particularly Pseudomonas aeruginosa.

Colistimethate Pharmacology

Colistimethate is a polymyxin antibiotic agent. Originally, colistimethate sodium was thought to be less toxic than polymyxin B; however, if the drugs are administered at comparable doses, their toxicities may be similar. Polymyxins are cationic polypeptides that disrupt the bacterial cell membrane through a detergentlike mechanism. With the development of less toxic agents, such as extended-spectrum penicillins and cephalosporins, parenteral polymyxin use was largely abandoned, except for the treatment of multidrug-resistant pulmonary infections in patients with cystic fibrosis. More recently, however, the emergence of multidrug-resistant gram-negative bacteria, such as Pseudomonas aeruginosa and Acinetobacter baumannii, and the lack of new antimicrobial agents have led to the revived use of the polymyxins.

Colistimethate Absorption

Very poor absorption from gastrointestinal tract.

Colistimethate side effects and Toxicity

Oral LD50 in rats is 5450 mg/kg. Overdosage with colistimethate can cause neuromuscular blockade characterized by paresthesia, lethargy, confusion, dizziness, ataxia, nystagmus, disorders of speech and apnea. Respiratory muscle paralysis may lead to apnea, respiratory arrest and death.

Colistimethate Patient Information

Colistimethate Organisms Affected

Gram-negative bacilli